Business
Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Poster published today at the 2021 American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from the
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"\n\nPoster published today at the 2021 American Association for Cancer Research (AACR) Annual Meeting shows the GP2 final 5 year immune response data from the Phase IIb clinical trial, concluding that GP2 immunotherapy generated GP2-specific immune responses leading to promising clinical benefit, thus supporting GP2’s mechanism of action.\n\n\n\nThe corresponding abstract can be viewed at the bottom of this press release and the full poster, Figures 1-3, and an audio track of the poster can be accessed or downloaded from the Clinical Trial tab of the Company website: https://greenwichlifesciences.com/clinical-trials/#Phase-IIb-AACR. The audio track, given by Dr. Jaye Thompson, Vice President of Clinical and Regulatory Affairs, can be directly played here: https://greenwichlifesciences.com/wp-content/uploads/2021/04/Thompson-Ph2-AACR-2021.m4a.\n\n\n\nImmune responses to GP2 were measured over time using a CD8 T cell dimer binding assay (Dimer Binding Assay) and delayed-type-hypersensitivity (DTH) skin tests. The Dimer Binding Assay detects the percentage of GP2 specific killer T cells that can kill recurring cancer cells. The DTH skin test measures the diameter of the skin immune response to GP2 in millimeters 48-72 hours after injection of GP2 without GM-CSF.\n\n\n\nFigure 1 of the poster shows that GP2 immunity peaked at 6 months in HER2 3+ patients after they completed their first 6 immunizations, as measured by the Dimer Binding Assay. The data also shows that for the 2.5 years that the immune response was measured, the immunity was sustained and remained above baseline, resulting in 100% disease free survival (0% recurrence rate) over 5 years. In the placebo arm, the immune response was not as robust, resulting in 89% disease free survival (11% recurrence rate).\n\n\n\nFigure 2 of the poster shows the same Dimer Binding Assay data for HER2 3+ patients as in Figure 1, where the GP2 treated patients showed statistically significant dimer readings versus baseline at 3, 6, and 12-13 months.\n\n\n\nFigure 3 of the poster shows that after completion of the 6th immunization after 6 months, GP2 treated patients showed a robust immune response using the DTH skin test, while the placebo did not (p = 0.009). Within GP2-treated patients, the change from baseline after 6 months was a median of 4.8 mm (mean of 11.6 mm), which was a statis...